A Study of BLB-201 RSV Vaccine in Infants and Children

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Respiratory Syncytial Virus Infections

In brief

This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) and children (18-59 months of age) who may or may not have had prior respiratory syncytial virus (RSV) infection.

Key facts

Study ID
NCT05655182
Run by
Blue Lake Biotechnology Inc.
People needed
137
Starts
2023-03-09
Expected to finish
2028-12-30
Last updated by the study team
2026-07-29

Who can join

Age: 1 and older, up to 5. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.